Ticagrelor mitigates ischaemia–reperfusion induced vascular endothelial dysfunction in healthy young males – a randomized, single‐blinded study

No abstract is available for this paper.

• Publication year

  2017

• Venue

  British Journal of Clinical Pharmacology

• Publication date

  2017-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/bcp.13378PMID 28715608PMCID PMC5698593
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Ticagrelor mitigates ischaemia–reperfusion induced vascular endothelial dysfunction in healthy young males – a randomized, single‐blinded study

  2017cited by this paper
• Pravastatin improves postprandial endothelial dysfunction and hemorheological deterioration in patients with effort angina pectoris

  2017cited by this paper
• Biological effects of ticagrelor over clopidogrel in patients with stable coronary artery disease and chronic obstructive pulmonary disease

  2017cited by this paper
• Ticagrelor and Rosuvastatin Have Additive Cardioprotective Effects via Adenosine

  2016cited by this paper
• The Concise Guide to PHARMACOLOGY 2015/16: G protein‐coupled receptors

  2015cited by this paper
• Ticagrelor Protects the Heart Against Reperfusion Injury and Improves Remodeling After Myocardial Infarction

  2015cited by this paper
• The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands

  2015cited by this paper
• Platelet P2Y12 Inhibitors Reduce Systemic Inflammation and Its Prothrombotic Effects in an Experimental Human Model

  2015cited by this paper
• Effect of systemic high dose vitamin C therapy on forearm blood flow reactivity during endotoxemia in healthy human subjects.

  2014cited by this paper
• Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance.

  2014cited by this paper
• Overview of pleiotropic effects of platelet P2Y12 receptor inhibitors

  2014cited by this paper
• Chronic Treatment With Ticagrelor Limits Myocardial Infarct Size: An Adenosine and Cyclooxygenase-2–Dependent Effect

  2014cited by this paper
• Morphine decreases clopidogrel concentrations and effects: a randomized, double-blind, placebo-controlled trial.

  2014cited by this paper
• Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome.

  2014cited by this paper
• Ramipril Protects the Endothelium from High Glucose–Induced Dysfunction through CaMKKβ/AMPK and Heme Oxygenase-1 Activation

  2014cited by this paper
• 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

  2013cited by this paper
• Stent Thrombosis With Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes: An Analysis From the Prospective, Randomized PLATO Trial

  2013cited by this paper
• NO-Dependent Endothelial Dysfunction in Type II Diabetes Is Aggravated by Dyslipidemia and Hypertension, but Can Be Restored by Angiotensin-Converting Enzyme Inhibition and Weight Loss

  2013cited by this paper
• Ticagrelor Improves Peripheral Arterial Function in Patients with a Previous Acute Coronary Syndrome

  2013cited by this paper
• 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

  2013cited by this paper
• ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation.

  2012cited by this paper
• 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC).

  2011cited by this paper
• Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator‐stimulated phosphoprotein phosphorylation assay

  2010cited by this paper
• Ticagrelor versus clopidogrel in patients with acute coronary syndromes.

  2009cited by this paper
• Intra-arterial vitamin C prevents endothelial dysfunction caused by ischemia-reperfusion.

  2008cited by this paper
• Roles of Oxidants, Nitric Oxide, and Asymmetric Dimethylarginine in Endothelial Function

  2008cited by this paper
• Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel

  2007cited by this paper
• Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.

  2007cited by this paper
• Clopidogrel Improves Systemic Endothelial Nitric Oxide Bioavailability in Patients With Coronary Artery Disease: Evidence for Antioxidant and Antiinflammatory Effects

  2006cited by this paper
• The role of oxidants and free radicals in reperfusion injury.

  2006cited by this paper
• Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects.

  2006cited by this paper
• Tetrahydrobiopterin corrects Escherichia coli endotoxin-induced endothelial dysfunction.

  2005cited by this paper
• Role of apoptosis in reperfusion injury.

  2004cited by this paper
• Reactive Oxygen Species: Players in the Platelet Game

  2004cited by this paper
• Platelet Glycoprotein IIb/IIIa Receptor Blockade Improves Vascular Nitric Oxide Bioavailability in Patients With Coronary Artery Disease

  2003cited by this paper
• L-arginine protects from ischemia-reperfusion-induced endothelial dysfunction in humans in vivo.

  2003cited by this paper
• Free radicals in the physiological control of cell function.

  2002cited by this paper
• Role of leukocytes and tissue-derived oxidants in short-term skeletal muscle ischemia-reperfusion injury.

  2000cited by this paper
• Progression of myocardial necrosis during reperfusion of ischemic myocardium.

  1998cited by this paper
• CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells

  1998cited by this paper
• L-arginine enhances functional recovery and Ca(2+)-dependent nitric oxide synthase activity after ischemia and reperfusion in the rat heart.

  1997cited by this paper
• The role of nitric oxide and cell adhesion molecules on the microcirculation in ischaemia-reperfusion.

  1996cited by this paper
• THE PATHOPHYSIOLOGICAL ROLE OF PEROXYNITRITE IN SHOCK, INFLAMMATION, AND ISCHEMIA‐REPERFUSION INJURY

  1996cited by this paper
• Close relation of endothelial function in the human coronary and peripheral circulations.

  1995cited by this paper
• An Electrically Calibrated Plethysmograph for Direct Measurement of Limb Blood Flow

  1975cited by this paper

• Increased nitrate intake from beetroot juice over 4 weeks affects nitrate metabolism, but not vascular function or blood pressure in older adults with hypertension

  2024cites this paper
• The Effect of Ticagrelor on Endothelial Function Compared to Prasugrel, Clopidogrel, and Placebo: A Systematic Review and Meta-Analysis

  2022cites this paper
• The effect of ticagrelor on microarterial thrombosis in an experimental model

  2021cites this paper
• Anticoagulants and Antiplatelet Drugs

  2021cites this paper
• Translation of experimental cardioprotective capability of P2Y12 inhibitors into clinical outcome in patients with ST-elevation myocardial infarction

  2021cites this paper
• One‐year efficacy and safety of prasugrel and ticagrelor in patients with acute coronary syndromes: Results from a prospective and multicentre ACHILLES registry

  2020cites this paper
• Co‐morbidities and co‐medications as confounders of cardioprotection—Does it matter in the clinical setting?

  2020cites this paper
• Ticagrelor Does Not Protect Against Endothelial Ischemia-Reperfusion Injury in Patients With Coronary Artery Disease

  2020cites this paper
• Prediction of Ticagrelor and its Active Metabolite in Liver Cirrhosis Populations Using a Physiologically Based Pharmacokinetic Model Involving Pharmacodynamics.

  2019cites this paper
• Effects of ticagrelor on the sodium/calcium exchanger 1 (NCX1) in cardiac derived H9c2 cells

  2019cites this paper
• Does Ticagrelor Improve Endothelial Function?

  2018cites this paper
• Ticagrelor mitigates ischaemia–reperfusion induced vascular endothelial dysfunction in healthy young males – a randomized, single‐blinded study

  2017cites this paper
• Atorvastatin combined with ticagrelor prevent ischemia-reperfusion induced vascular endothelial dysfunction in healthy young males - A randomized, placebo-controlled, double-blinded study.

  2017cites this paper